129
Participants
Start Date
February 28, 2014
Primary Completion Date
June 5, 2017
Study Completion Date
June 5, 2017
intravitreal ranibizumab 0.3 mg
Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
dexamethasone intravitreal implant
The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
Sham injection
No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
MaculaCare, New York
Retina Associates of Western New York, Rochester
University of Rochester, Rochester
University of Pennsylvania Scheie Eye Institute, Philadelphia
Virginia Retina Center, Leesburg
Elman Retina Group, P.A., Baltimore
Retina Institute of Virginia, Richmond
Charlotte Eye Ear Nose and Throat Assoc, PA, Charlotte
Thomas Eye Group, Sandy Springs
Southeast Retina Center, P.C., Augusta
University of Florida College of Med., Department of Ophthalmology, Jacksonville
Retina Associates of Florida, P.A., Tampa
Central Florida Retina Institute, Lakeland
National Ophthalmic Research Institute, Fort Myers
Sarasota Retina Institute, Sarasota
Ocala Eye Retina Consultants, Ocala
Southeastern Retina Associates, P.C., Knoxville
Case Western Reserve University, Cleveland
Retina Associates of Cleveland, Inc., Beachwood
Raj K. Maturi, M.D., P.C., Indianapolis
Retina Vitreous Center, Grand Blanc
Retina Specialists of Michigan, Grand Rapids
Wolfe Eye Clinic, West Des Moines
Medical Associates Clinic, P.C., Dubuque
University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison
Retina Center, PA, Minneapolis
The Retina Institute, St Louis
Retina Associates, P.A., Shawnee Mission
Retina and Vitreous of Texas, Houston
Baylor Eye Physicians and Surgeons, Houston
Retina Consultants of Houston, PA, Houston
Retinal Consultants of San Antonio, San Antonio
Valley Retina Institute, McAllen
Austin Retina Associates, Austin
Retina Research Center, Austin
Southwest Retina Specialists, Amarillo
Texas Retina Associates, Lubbock
Retina Associates of Utah, P.C., Salt Lake City
Retina-Vitreous Associates Medical Group, Beverly Hills
Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda
Retina Consultants of Southern California, Redlands
Atlantis Eye Care, Huntington Beach
California Retina Consultants, Santa Barbara
Northern California Retina Vitreous Associates, Mountain View
Bay Area Retina Associates, Walnut Creek
Retinal Consultants Medical Group, Inc., Sacramento
Retina Northwest, PC, Portland
Casey Eye Institute, Portland
University of Washington Medical Center, Seattle
Spokane Eye Clinic, Spokane
Retina Group of New England, New London
New England Retina Associates, Norwich
National Eye Institute/National Institutes of Health, Bethesda
Ophthalmic Consultants of Boston, Boston
Joslin Diabetes Center, Boston
The Institute of Ophthalmology and Visual Science (IOVS), Newark
Lead Sponsor
Collaborators (2)
Allergan
INDUSTRY
Genentech, Inc.
INDUSTRY
National Eye Institute (NEI)
NIH
Jaeb Center for Health Research
OTHER